Zymeworks Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Zymeworks' Board authorized a second 2026 share repurchase program of up to $200 million through 2028, with the company expecting to deploy $140 million of that authorization. As of November 11, 2026, the company had 68.7 million outstanding shares. Funding will come from existing balance sheet plus $55 million in expected Roche collaboration upfront fees and potential $100 million TRELEGY ELLIPTA milestone payment in Q1 2027.
Why this rating
Repurchase authorization of $140M expected deployment is ~22% of $649.5M market cap—meaningful but not transformational. Contingent on Roche deal and milestone achievements. Flexible program with no obligation. Moderate capital allocation signal.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.